Experimental blood cancer drug trial halted early

NCT ID NCT04240704

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called JBH492 in 25 people with two types of blood cancer (chronic lymphocytic leukemia and non-Hodgkin's lymphoma) that had returned or stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA NON-HODGKINS LYMPHOMA

Contacts and locations

Locations

Novartis Investigative Site

Helsinki, FIN-00029, Finland
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Freiburg im Breisgau, 79106, Germany
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Chuo Ku, Tokyo, 104 0045, Japan
Novartis Investigative Site

Singapore, 169608, Singapore
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.